Pharmacological options in the treatment of acromegaly

Current Opinion in Investigational Drugs

Volumn 6, Issue 10, 2005, Pages 1023-1027

  Ezzat, Shereen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acromegaly; GH antagonist; Growth hormone; Pituitary tumor; Somatostatin

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ACROMEGALY; CHOLELITHIASIS; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG COST; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SPECIFICITY; EVIDENCE BASED MEDICINE; GALLBLADDER DISEASE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HEALTH CARE COST; HUMAN; HYPOPHYSIS ADENOMA; LIVER TOXICITY; MALABSORPTION; MORTALITY; ORTHOSTATIC HYPOTENSION; PROTEIN BLOOD LEVEL; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SOMNOLENCE;

ACROMEGALY; ANIMALS; GROWTH HORMONE; HUMANS; NEUROSURGICAL PROCEDURES; PITUITARY NEOPLASMS; RADIOTHERAPY; SOMATOSTATIN;

EID: 27544499538     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Asa SL, Ezzat S: The pathogenesis of pituitary tumours. Nat Rev Cancer (2002) 2(11):836-849.
2. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K: In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol (1995) 133(6):686-690.
3. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB et al: Octreotide treatment of acromegaly: A randomized multicenter study. Ann Intern Med (1992) 117(9):711-718.
4. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG: Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) (1994) 73(5):233-240.
5. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM et al: Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab (2002) 87(10):4554-4563
6. Bevan JS: Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab (2005) 90(3):1856-1863.
7. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D: Long-acting somatostatin analog therapy of acromegaly: A meta-analysis. J Clin Endocrinol Metab (2005) 90(8):4465-4473.
8. Reubi JC, Landolt AM: The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Melab (1989) 68(4):844-850.
9. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A: Somatostatin receptor-specific analogs: Effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab (2001) 86(7):2976-2981.
10. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S: The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab (2005): doi:10.1210/jc.2005-0998.
11. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels; F, Coolens JL, Mahler C, Backers A: Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab (1998) 83(2):374-378.
12. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D: Cabergoline in acromegaly: A renewed role for dopamine agonist treatment? Eur J Endocrinol (1998) 139(5):516-521.
13. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 358(9295):1754-1759.
14. AACE Acromegaly Guidelines Task Force: AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract (2004) 10(3):213-225.
15. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 342(16):1171-1177.
16. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Van Warder K, Melmed S: Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Melab (2000) 85(2):526-529.
17. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab (1998) 83(10):3419-3426.
18. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegely. J Clin Endocrinol Metab (2001) 86(6):2779-2786.
19. Colao A, Marzullo P, Spiezia S, Giaccio A, Ferone D, Cerbone G, Di Sarno A, Lombardi G: Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab (2000) 85(10):3754-3761.
20. Colao A, Marzullo R Vallone G, Giaccio A, Ferone D, Rossi E, Scarpa R, Smaltino F, Lombardi G: Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) (1999) 51(5):611-618.
21. Ip MS, Tan KC, Peh WC, Lam KS: Effect of Sandostatin LAR on sleep apnoea in acromegaly: Correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) (2001) 55(4):477-483.
22. Koop BL, Harris AG, Ezzat S: Effect of octreotide, on glucose tolerance in acromegaly. Eur J Endocrinol (1994) 130(6):581-586.
23. Wilson LS, Shin JL, Ezzat S: Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract (2001) 7(3):170-180.
24. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A: Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol (2005) 152(1):61-66.
25. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen J-W, Kristensen LO, Hagen C, Orskov H: Cotreatment of acromegaly with a somatostatin analogue and a growth hormone receptor antagonist. J Clin Endocrinol Metab (2005): doi:10.1210/jc.2005-0531.
26. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet (2005) 365(9471):1644-1646.